(Q44767628)

6 December 2017

title

Mechanism of antiviral activities of 3'-substituted L-nucleosides against 3TC-resistant HBV polymerase: a molecular modelling approach (English)

1 reference

6 December 2017

4

Raymond F Schinazi

1 reference

6 December 2017

5

Chung K Chu

1 reference

6 December 2017

2

Lieven Stuyver

1 reference

6 December 2017

1

Youhoon Chong

1 reference

6 December 2017

Michael J Otto

3

1 reference

6 December 2017

publication date

1 November 2003

1 reference

Antiviral Chemistry & Chemotherapy

6 December 2017

published in

1 reference

6 December 2017

volume

14

1 reference

6 December 2017

issue

6

1 reference

6 December 2017

page(s)

309-319

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Unusual structural features of 2',3'-dideoxycytidine, an inhibitor of the HIV (AIDS) virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Antiviral L-nucleosides specific for hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Molecular mechanism of DApd/DXG against zidovudine- and lamivudine- drug resistant mutants: a molecular modelling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Organic Fluorine Hardly Ever Accepts Hydrogen Bonds

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Synthesis and potent anti-HIV activity of L-3'-fluoro-2',3'-unsaturated cytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

The treatment of chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2 restricted cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Antiviral activity of 2',3'-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2',3'-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Design and synthesis of 2',3'-dideoxy-2',3'-didehydro-beta-L-cytidine (beta-L-d4C) and 2',3'-dideoxy 2',3'-didehydro-beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: role of the 3'-hydroxyl group of the L-(beta)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Compact organization of the hepatitis B virus genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

An all atom force field for simulations of proteins and nucleic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

21 January 2018

The hepatitis B virus

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020301400603

10.1177/095632020301400603

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference